<p>阿卡迪亚制药公司（NASDAQ:ACAD - 获取免费报告）在周三上涨了 3.5%，因为德意志银行将该股票的目标价上调至 35.00 美元。德意志银行目前对该股票给予买入评级。阿卡迪亚制药的交易最高达到 22.75 美元，最后交易价格为 22.44 美元。在午盘交易中，376,453 股易手，较平均交易量 2,372,912 股下降了 84%。该股票此前收盘价为 21.69 美元。</p>
<p>获取 <strong>阿卡迪亚制药</strong> 的提醒：</p>
<ul>
<li>阿卡迪亚制药：一家中型生物科技公司正在大幅波动</li>
</ul>
<p>其他分析师最近也发布了关于该股票的研究报告。Cantor Fitzgerald 在 2 月 27 日的研究报告中重申了 “增持” 评级，并将阿卡迪亚制药的目标价设定为 28.00 美元。加拿大皇家银行在周一的研究报告中重申了 “跑赢大盘” 评级，并对阿卡迪亚制药的股票设定了 26.00 美元的目标价。BMO 资本市场在周一将阿卡迪亚制药的目标价从 24.00 美元上调至 28.00 美元，并给予该公司 “跑赢大盘” 评级。Oppenheimer 在周五的研究报告中重申了阿卡迪亚制药的 “市场表现” 评级。最后，HC Wainwright 在周一将阿卡迪亚制药的目标价从 27.00 美元上调至 32.00 美元，并给予该公司 “买入” 评级。六位研究分析师对该股票给予持有评级，九位分析师对该公司给予买入评级。根据 MarketBeat.com 的数据，阿卡迪亚制药目前的平均评级为 “适度买入”，共识目标价为 26.83 美元。</p>
<p><strong>阅读我们关于阿卡迪亚制药的最新股票分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他消息中，执行副总裁 Mark C. Schneyer 在 3 月 26 日的交易中出售了 3,171 股公司股票。这些股票以平均价格 17.05 美元出售，总交易额为 54,065.55 美元。交易完成后，该执行副总裁现在直接拥有 56,889 股公司股票，价值约为 969,957.45 美元。这代表其持股比例下降了 5.28%。该出售在与 SEC 的法律文件中披露，可以通过此超链接访问。此外，董事 Elizabeth A. Garofalo 在 3 月 5 日的交易中出售了 4,919 股公司股票。这些股票以平均价格 18.23 美元出售，总交易额为 89,673.37 美元。交易完成后，该董事现在直接拥有 17,595 股公司股票，价值约为 320,756.85 美元。这笔交易代表其持股比例下降了 21.85%。该出售的披露信息可以在此找到。内部人士在过去三个月内出售了价值 453,131 美元的 24,994 股公司股票。内部人士持有公司 26.50% 的股份。</p>
<h2>机构投资者对阿卡迪亚制药的看法</h2>
<p>对冲基金和其他机构投资者最近买卖了该公司的股票。Exchange Traded Concepts LLC 在第一季度购买了阿卡迪亚制药的新头寸，价值约 29,000 美元。Banque Transatlantique SA 在第一季度购买了阿卡迪亚制药的新头寸，价值约 31,000 美元。Picton Mahoney 资产管理在第一季度购买了阿卡迪亚制药的新头寸，价值约 32,000 美元。Federated Hermes Inc.在第一季度将其在阿卡迪亚制药的持股增加了 231.5%。Federated Hermes Inc.现在拥有 2,317 股该生物制药公司的股票，价值 38,000 美元，此前在该期间内又购买了 1,618 股。最后，Virtus Fund Advisers LLC 在第四季度购买了阿卡迪亚制药的新头寸，价值约 39,000 美元。对冲基金和其他机构投资者持有公司 96.71% 的股份。</p>
<h2>阿卡迪亚制药的价格表现</h2>
<p>该公司的市值为 37.6 亿美元，市盈率为 28.77，贝塔值为 0.47。该股票的 50 日移动平均线为 16.11 美元，200 日移动平均线为 17.19 美元。</p>
<p>阿卡迪亚制药（NASDAQ:ACAD - 获取免费报告）最近在 5 月 7 日发布了季度财报。该生物制药公司报告每股收益为 0.11 美元，超出分析师一致预期的 0.10 美元，超出 0.01 美元。该公司季度收入为 2.4432 亿美元，而共识预期为 2.3932 亿美元。阿卡迪亚制药的净利润率为 13.83%，股本回报率为 25.83%。该公司季度收入较去年同期增长了 18.7%。在去年同期，该公司每股收益为 0.10 美元。分析师平均预测阿卡迪亚制药将在当前年度发布 0.7 美元的每股收益。</p>
<h2>阿卡迪亚制药公司简介</h2>
<p>（获取免费报告）</p>
<p>阿卡迪亚制药公司是一家生物制药公司，专注于开发和商业化创新药物，以满足美国中枢神经系统（CNS）疾病和罕见疾病的未满足医疗需求。该公司提供 NUPLAZID（pimavanserin）用于治疗与帕金森病精神病相关的幻觉和妄想；以及 DAYBUE，一种合成的胰岛素样生长因子 1 氨基端三肽的新型合成类似物，用于治疗 Rett 综合症。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过阿卡迪亚制药</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>Rivian 股票低于 20 美元：充电中还是在故障车道？</li>
<li>如何使用股票筛选器寻找股票</li>
<li>2025 年最佳公用事业股票以实现稳定和增长</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>高通重返 CPU 市场可能不够</li>
</ul>
<p><em>此即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 ACADIA Pharmaceuticals 吗？</h2>
<p>在考虑 ACADIA Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ACADIA Pharmaceuticals 并不在名单上。</p>
<p>虽然 ACADIA Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿卡迪亚

<p>ACADIA Pharmaceuticals（纳斯达克代码：ACAD）股价上涨 3.5%，因德意志银行将其目标价上调至 35.00 美元，并维持买入评级。该股票交易价格为 22.44 美元，交易量显著下降。其他分析师也发布了积极评级，目标价范围在 26.00 美元至 32.00 美元之间。内部人士最近出售了部分股份，机构投资者持有 96.71% 的股份。公司报告的季度每股收益为 0.11 美元，超出预期，营收同比增长 18.7%</p>

<p>ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) shot up 3.5% on Wednesday after Deutsche Bank Aktiengesellschaft raised their price target on the stock to $35.00. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. ACADIA Pharmaceuticals traded as high as $22.75 and last traded at $22.44. 376,453 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 2,372,912 shares. The stock had previously closed at $21.69.</p>
<div class="lb-trans"><p>阿卡迪亚制药公司（NASDAQ:ACAD - 获取免费报告）在周三上涨了 3.5%，因为德意志银行将该股票的目标价上调至 35.00 美元。德意志银行目前对该股票给予买入评级。阿卡迪亚制药的交易最高达到 22.75 美元，最后交易价格为 22.44 美元。在午盘交易中，376,453 股易手，较平均交易量 2,372,912 股下降了 84%。该股票此前收盘价为 21.69 美元。</p>
</div><p>Get <strong>ACADIA Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>阿卡迪亚制药</strong> 的提醒：</p>
</div><ul>
<li>Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves</li>
</ul>
<div class="lb-trans"><ul>
<li>阿卡迪亚制药：一家中型生物科技公司正在大幅波动</li>
</ul>
</div><p>Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Royal Bank of Canada reaffirmed an &#34;outperform&#34; rating and issued a $26.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday. BMO Capital Markets raised their price target on shares of ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday. Oppenheimer reiterated a &#34;market perform&#34; rating on shares of ACADIA Pharmaceuticals in a research note on Friday. Finally, HC Wainwright lifted their price objective on shares of ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $26.83.</p>
<div class="lb-trans"><p>其他分析师最近也发布了关于该股票的研究报告。Cantor Fitzgerald 在 2 月 27 日的研究报告中重申了 “增持” 评级，并将阿卡迪亚制药的目标价设定为 28.00 美元。加拿大皇家银行在周一的研究报告中重申了 “跑赢大盘” 评级，并对阿卡迪亚制药的股票设定了 26.00 美元的目标价。BMO 资本市场在周一将阿卡迪亚制药的目标价从 24.00 美元上调至 28.00 美元，并给予该公司 “跑赢大盘” 评级。Oppenheimer 在周五的研究报告中重申了阿卡迪亚制药的 “市场表现” 评级。最后，HC Wainwright 在周一将阿卡迪亚制药的目标价从 27.00 美元上调至 32.00 美元，并给予该公司 “买入” 评级。六位研究分析师对该股票给予持有评级，九位分析师对该公司给予买入评级。根据 MarketBeat.com 的数据，阿卡迪亚制药目前的平均评级为 “适度买入”，共识目标价为 26.83 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on ACADIA Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于阿卡迪亚制药的最新股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, EVP Mark C. Schneyer sold 3,171 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the completion of the transaction, the executive vice president now directly owns 56,889 shares of the company's stock, valued at approximately $969,957.45. This represents a 5.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the transaction, the director now directly owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This trade represents a 21.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,994 shares of company stock valued at $453,131 over the last three months. Insiders own 26.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Mark C. Schneyer 在 3 月 26 日的交易中出售了 3,171 股公司股票。这些股票以平均价格 17.05 美元出售，总交易额为 54,065.55 美元。交易完成后，该执行副总裁现在直接拥有 56,889 股公司股票，价值约为 969,957.45 美元。这代表其持股比例下降了 5.28%。该出售在与 SEC 的法律文件中披露，可以通过此超链接访问。此外，董事 Elizabeth A. Garofalo 在 3 月 5 日的交易中出售了 4,919 股公司股票。这些股票以平均价格 18.23 美元出售，总交易额为 89,673.37 美元。交易完成后，该董事现在直接拥有 17,595 股公司股票，价值约为 320,756.85 美元。这笔交易代表其持股比例下降了 21.85%。该出售的披露信息可以在此找到。内部人士在过去三个月内出售了价值 453,131 美元的 24,994 股公司股票。内部人士持有公司 26.50% 的股份。</p>
</div><h2>Institutional Investors Weigh In On ACADIA Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对阿卡迪亚制药的看法</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. Exchange Traded Concepts LLC bought a new position in shares of ACADIA Pharmaceuticals in the first quarter worth approximately $29,000. Banque Transatlantique SA bought a new position in ACADIA Pharmaceuticals during the first quarter valued at approximately $31,000. Picton Mahoney Asset Management bought a new position in ACADIA Pharmaceuticals during the first quarter valued at approximately $32,000. Federated Hermes Inc. lifted its position in ACADIA Pharmaceuticals by 231.5% during the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 1,618 shares during the period. Finally, Virtus Fund Advisers LLC bought a new position in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $39,000. Hedge funds and other institutional investors own 96.71% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买卖了该公司的股票。Exchange Traded Concepts LLC 在第一季度购买了阿卡迪亚制药的新头寸，价值约 29,000 美元。Banque Transatlantique SA 在第一季度购买了阿卡迪亚制药的新头寸，价值约 31,000 美元。Picton Mahoney 资产管理在第一季度购买了阿卡迪亚制药的新头寸，价值约 32,000 美元。Federated Hermes Inc.在第一季度将其在阿卡迪亚制药的持股增加了 231.5%。Federated Hermes Inc.现在拥有 2,317 股该生物制药公司的股票，价值 38,000 美元，此前在该期间内又购买了 1,618 股。最后，Virtus Fund Advisers LLC 在第四季度购买了阿卡迪亚制药的新头寸，价值约 39,000 美元。对冲基金和其他机构投资者持有公司 96.71% 的股份。</p>
</div><h2>ACADIA Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>阿卡迪亚制药的价格表现</h2>
</div><p>The company has a market cap of $3.76 billion, a P/E ratio of 28.77 and a beta of 0.47. The stock's 50-day moving average is $16.11 and its two-hundred day moving average is $17.19.</p>
<div class="lb-trans"><p>该公司的市值为 37.6 亿美元，市盈率为 28.77，贝塔值为 0.47。该股票的 50 日移动平均线为 16.11 美元，200 日移动平均线为 17.19 美元。</p>
</div><p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The company had revenue of $244.32 million for the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm's revenue for the quarter was up 18.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share. On average, analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.</p>
<div class="lb-trans"><p>阿卡迪亚制药（NASDAQ:ACAD - 获取免费报告）最近在 5 月 7 日发布了季度财报。该生物制药公司报告每股收益为 0.11 美元，超出分析师一致预期的 0.10 美元，超出 0.01 美元。该公司季度收入为 2.4432 亿美元，而共识预期为 2.3932 亿美元。阿卡迪亚制药的净利润率为 13.83%，股本回报率为 25.83%。该公司季度收入较去年同期增长了 18.7%。在去年同期，该公司每股收益为 0.10 美元。分析师平均预测阿卡迪亚制药将在当前年度发布 0.7 美元的每股收益。</p>
</div><h2>ACADIA Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>阿卡迪亚制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.</p>
<div class="lb-trans"><p>阿卡迪亚制药公司是一家生物制药公司，专注于开发和商业化创新药物，以满足美国中枢神经系统（CNS）疾病和罕见疾病的未满足医疗需求。该公司提供 NUPLAZID（pimavanserin）用于治疗与帕金森病精神病相关的幻觉和妄想；以及 DAYBUE，一种合成的胰岛素样生长因子 1 氨基端三肽的新型合成类似物，用于治疗 Rett 综合症。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than ACADIA Pharmaceuticals</li>
<li>How to buy stock: A step-by-step guide for beginners</li>
<li>Rivian Stock Below $20: Charging Up or in the Breakdown Lane?</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Best Utilities Stocks for Stability and Growth in 2025</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Qualcomm’s Re-Entry Into the CPU Market May Not Be Enough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过阿卡迪亚制药</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>Rivian 股票低于 20 美元：充电中还是在故障车道？</li>
<li>如何使用股票筛选器寻找股票</li>
<li>2025 年最佳公用事业股票以实现稳定和增长</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>高通重返 CPU 市场可能不够</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ACADIA Pharmaceuticals 吗？</h2>
</div><p>Before you consider ACADIA Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 ACADIA Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ACADIA Pharmaceuticals 并不在名单上。</p>
</div><p>While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ACADIA Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿卡迪亚制药公司（NASDAQ:ACAD）的股价在分析师上调评级后上涨了 3.5%